The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact on turnaround times (TAT) among non-squamous non-small cell lung cancer (NSCLC) patients across three time periods with varying biomarker testing techniques.
 
Zhen (Jason) Fan
No Relationships to Disclose
 
Roxana Tudor
No Relationships to Disclose
 
Lisa W Le
No Relationships to Disclose
 
Jennifer H. Law
No Relationships to Disclose
 
Andrea S. Fung
No Relationships to Disclose
 
Shelley Kuang
No Relationships to Disclose
 
Nicholas Meti
Honoraria - Novartis; Takeda
Consulting or Advisory Role - AstraZeneca; Pfizer; Seagen; Takeda
Travel, Accommodations, Expenses - Novartis Canada Pharmaceuticals Inc
 
Kirstin Perdrizet
Honoraria - Amgen; Merck; Pfizer
Consulting or Advisory Role - Amgen; Merck; Takeda
Travel, Accommodations, Expenses - Roche
 
Laura Ranich
No Relationships to Disclose
 
Cuihong Wei
No Relationships to Disclose
 
Peter Sabatini
No Relationships to Disclose
 
Prodipto Pal
No Relationships to Disclose
 
Ming Sound Tsao
Honoraria - Sanofi/Regeneron
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Lilly
Speakers' Bureau - Abbvie; Sanofi
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Sanofi (Inst)
 
Geoffrey Liu
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Jazz Pharmaceuticals; Merck; novartis; pfizer; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; novartis; pfizer; Roche Canada; takeda
Speakers' Bureau - AstraZeneca; Pfizer; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; roche (Inst); Takeda
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Daiichi Sankyo; Merck Serono; Takeda
Consulting or Advisory Role - AstraZeneca; Merck Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Penelope Ann Bradbury
Consulting or Advisory Role - Mirati Therapeutics
(OPTIONAL) Uncompensated Relationships - Abbvie; Bristol-Myers Squibb
 
Adrian G. Sacher
Research Funding - AstraZeneca; BMS; Genentech/Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Genentech/Roche
 
Lawson Eng
No Relationships to Disclose
 
Michael Cabanero
No Relationships to Disclose
 
Natasha B. Leighl
Research Funding - Amgen (Inst); AstraZeneca Canada (Inst); Bayer (Inst); EMD Serono (Inst); Guardant Health (Inst); Lilly (Inst); MSD (Inst); MSD Oncology (Inst); Roche Canada (Inst); Roche Canada (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme